title: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
abstract: OBJECTIVE
  A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas.
  
  
  METHODS
  Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors.
  
  
  RESULTS
  The oligodendroglial phenotype was highly associated with loss of 1p (P =.0002), loss of 19q (P <.0001), and combined loss of 1p and 19q (P <.0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log-rank, P =.03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P <.01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma.
  
  
  CONCLUSIONS
  Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management.
authors.affiliation: Division of Laboratory Genetics, Division of Anatomic Pathology, Department of Neurology, and Section of Biostatistics, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Smith
authors.forename: A
authors.initials: A
authors.lastname: Perry
authors.forename: T J
authors.initials: TJ
authors.lastname: Borell
authors.forename: H K
authors.initials: HK
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: O'Fallon
authors.forename: S M
authors.initials: SM
authors.lastname: Hosek
authors.forename: D
authors.initials: D
authors.lastname: Kimmel
authors.forename: A
authors.initials: A
authors.lastname: Yates
authors.forename: P C
authors.initials: PC
authors.lastname: Burger
authors.forename: B W
authors.initials: BW
authors.lastname: Scheithauer
authors.forename: R B
authors.initials: RB
authors.lastname: Jenkins
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001254:Astrocytoma / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D002648:Child; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1; D002888:Chromosomes, Human, Pair 19; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D011237:Predictive Value of Tests; D011446:Prospective Studies; D016019:Survival Analysis